Effect of liraglutide combined with zoledronic acid and calcium carbonate D3 in the treatment of diabetic osteoporosis and its influences on OPG and Apelin-13
Objective To investigate the effect of liraglutide combined with zoledronic acid and calcium carbonate D3 in the treatment of diabetic osteoporosis and its influences on osteoprotegerin(OPG)and Apelin-13.Methods A total of 150 patients with diabetic osteoporosis admitted from January 2020 to March 2022 were selected as the research objects.According to the random number table method,the patients were divided into control group and observation group,with 75 cases in each group.The control group was treated with zoledronic acid and calcium carbonate D3,and the observation group was treated with liraglutide on the basis of the control group.The therapeutic effect,OPG,Apelin-13 levels,glucose metabolism and bone metabolism indexes were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of OPG and Apelin-13 in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of glycosylated hemoglobin(HbA1c),fasting plasma glucose(FPG)and fasting insulin(FINS)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of bone alkaline phosphatase(BALP)and secreted frizzled-related protein 5(SFRP5)in the observation group were higher than those in the control group,and the level of β-C-terminal telopeptide of typeⅠcollagen(β-CTX)was lower than that in the control group(P<0.05).Conclusion Liraglutide combined with zoledronic acid and calcium carbonate D3 in the treatment of diabetic osteoporosis can elevate the clinical effect,improve the indexes of glucose metabolism and bone metabolism,and regulate the levels of OPG and Apelin-13.
NETL
NSTL
万方数据
